...
首页> 外文期刊>International Scholarly Research Notices >Treatment of Primary Axillary Hyperhidrosis with Botulinum Toxin Type A: Our Experience in 50 Patients from 2007 to 2010
【24h】

Treatment of Primary Axillary Hyperhidrosis with Botulinum Toxin Type A: Our Experience in 50 Patients from 2007 to 2010

机译:A型肉毒杆菌毒素治疗原发性腋窝多汗症:我们从2007年至2010年的50例患者中的经验

获取原文

摘要

Background. Local injections of Botulinum toxin type A (BTX-A) are an effective and safe solution for primary bilateral axillary hyperhidrosis. Traditional treatments are often ineffective and difficult to tolerate. This study was performed to assess the efficacy and safety of Botulinum toxin type A in the treatment of these diseases and to evaluate the reliability of patient’s subjective rating in the timing of repeat injections.Methods. From 2007 to 2008, we included in the study and treated a total of 50 patients, and we used the Minor’s iodine test and the hyperhidrosis diseases severity scale as initial inclusion criteria and also for evaluating the followup, comparing to patient’s subjective rating. We used also a specific questionnaire to evaluate the level of pain, the onset of the effect, any eventual adverse effect of the treatment, the onset of compensatory hyperhidrosis, and the global grade of satisfaction. The data were analyzed using standard statistical methods.Results. 88% of patients were totally satisfied and all patients repeated the treatment during all the study. The symptom-free interval was in median 6 months with an average improving of HDSS of 1.5 points. In 86%, there was a complete accordance between the subjective patient’s demand of the repetition of the treatment and the positivity to Minor test and HDSS. No major side effects happened.Conclusion. Local injections of Botulinum toxin type A (BTX-A) result in an effective and safe solution for bilateral axillary primary hyperhidrosis for the absence of significant morbidity, side effects, and lack of efficacy or duration. The only defects are the need of repetition of the treatment and relative costs.
机译:背景。局部注射A型肉毒杆菌毒素(BTX-A)是治疗原发性双侧腋窝多汗症的有效且安全的解决方案。传统疗法通常无效且难以忍受。这项研究的目的是评估A型肉毒毒素在治疗这些疾病中的功效和安全性,并评估患者在重复注射时的主观评分的可靠性。从2007年到2008年,我们纳入了该研究并治疗了50名患者,我们使用Minor碘试验和多汗症严重程度量表作为初始纳入标准,并与患者的主观评分进行比较,以评估随访情况。我们还使用了专门的问卷来评估疼痛程度,起效,治疗的任何最终不良反应,代偿性多汗症的发作以及总体满意度。使用标准统计方法分析数据。 88%的患者完全满意,所有患者在整个研究过程中都重复了治疗。无症状间隔为中位6个月,HDSS平均改善1.5点。在86%的患者中,主观患者对重复治疗的需求与对次要检查和HDSS的阳性反应完全一致。没有重大的副作用发生。局部注射A型肉毒杆菌毒素(BTX-A)可为双侧腋窝原发性多汗症提供有效而安全的解决方案,因为它没有明显的发病率,副作用以及缺乏疗效或持续时间。唯一的缺陷是需要重复治疗和相关费用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号